Evidence map›Paper›PMID 40281597›Full record

ArticleTrials2025

Respiratory biofeedback and psycho-education for patients with post COVID- 19 symptoms and bodily distress: study protocol of the randomized, controlled explorative intervention trial POSITIV.

Hannah Dinse, Eva-Maria Skoda, Adam Schweda, Christoph Jansen, Kira Schmidt, Margarethe Konik, Hana Rohn, Oliver Witzke, Mark Stettner, Christoph Kleinschnitz and 2 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hannah DinseClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany. hannah.dinse@lvr.de.ORCID http://orcid.org/0000-0002-8855-2699
Eva-Maria SkodaClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Adam SchwedaClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Christoph JansenClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Kira SchmidtClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Margarethe KonikDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Hana RohnDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Oliver WitzkeDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Mark StettnerDepartment of Neurology, University Medicine Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Christoph KleinschnitzDepartment of Neurology, University Medicine Essen, University of Duisburg-Essen, Hufelandstrasse 55, Essen, 45147, Germany.
Alexander BäuerleClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.
Martin TeufelClinic for Psychosomatic Medicine and Psychotherapy, LVR-University Hospital, University of Duisburg-Essen, Virchowstraße 174, Essen, 45147, Germany.

Funding

DFG Clinician Scientist Program UMEA FU 356/12-2
6 · The paper itself

Abstract

backgroundA high number of individuals report suffering from physical and psychological sequelae symptoms after COVID-19-the so-called post COVID-19 condition. Commonly reported complaints include physical symptoms such as fatigue, headache, attention and concentration deficits or dyspnea and anxiety, symptoms of post-traumatic stress, or depression. Evidence-based treatment recommendations are still lacking up to this point. Associations between physical and psychological symptoms in chronic diseases are known for a long time. Support in coping with the disease and improvement of self-efficacy can have a positive effect on the course of diseases. For this reason, we designed a randomized, controlled explorative intervention trial as a treatment of bodily distress disorder in COVID-19 recovered persons.

methodsPatients with a post COVID-19 condition meeting to the criteria of the WHO, along with a bodily distress disorder, are randomized in an intervention and control arm (TAU). Randomization takes place after a diagnostic interview, screening, and informed consent. In total, 60 patients will be included in the trial (30 per group). The intervention group receives a cognitive behavioral therapy as a video-conference-based group therapy (6 weeks) and mobile, respiratory biofeedback treatment (for 4 weeks). At several time points, both groups are assessed in terms of psychological and physical health status, treatment expectation, and satisfaction with the intervention. Furthermore, they will get biofeedback examination appointments. The primary outcome is the change in self-efficacy; secondary outcomes include assessed parameters of mental health, somatic symptoms, and satisfaction with the intervention. Data will be analyzed primarily using R and SPSS. DISCUSSION: The randomized, controlled, explorative intervention trial POSITIV is one of the very first interventions for patients with post COVID-19 condition and psychological burden due to their different symptoms. The aim of the study is to generate new evidence and help patients to cope with the disease and thus, increase their quality of life and reduce symptomatology. We expect with a high probability that the patients' self-efficacy and health status will improve as a result of the intervention.

trial registrationGerman Clinical Trial Register (DRKS); DRKS-ID: DRKS00030565. Registered on December 22, 2022.

Indexed as

Biofeedback, PsychologyCognitive Behavioral TherapyCOVID-19Patient Education as TopicAdaptation, PsychologicalBreathing ExercisesHumansPost-Acute COVID-19 SyndromeQuality of LifeRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeBiofeedbackBodily distress disorderCognitive behavioral therapyLong COVID- 19PsychosomaticPsychotherapyRandomized controlled trialSARS-CoV- 2Somatic symptom disorder

Identifiers

PMID40281597
PMCPMC12032681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.